Genitourinary syndrome of menopause in patients with breast cancer treated by hormonotherapy: women's perception in ITAC, a French web-based survey - 23/03/24
, Carine Martin 3, Patrice Lopes 4, Florence Coussy 5Highlights |
• | Web-based survey in women treated by hormonotherapy (HT) for breast cancer (BC) to investigate incidence and impact of GUSM. |
• | Among 1157 participants, 96.4 % reported at least one GUSM symptom. Median (range) number of GUSM symptoms was 6 (0–14). |
• | Most important impact reported for sexual life followed by psychological condition/self-image and relations with partners. |
• | Only 13.6 % of participants had received information on GUSM prior to the survey. |
• | Women should be informed about GUSM, symptoms should be detected and managed early to avoid impaired quality of life. |
Summary |
Objective |
To describe frequency, intensity and impact of genito-urinary syndrome of menopause (GUSM) in breast cancer (BC) survivors receiving hormonotherapy (HT).
Methods |
Web-based survey hosted on the Seintinelles website (database of patients and caregivers). Specific questionnaire of 43 questions, including sociodemographic characteristics, history of BC, characteristics of HT, side effects other than GUSM, symptoms of GUSM (frequency, intensity, treatment, and impact) and overall expectations regarding treatment.
Results |
Among 1157 participants, 96.4% had at least one GUSM symptom. Percentages with at least one urinary, gynecological, or sexual symptom were 56.0%, 85.6% and 86.1% respectively while 70.3% and 10% declared at least 5 and 10 symptoms respectively. Mean (SD) and median (range) numbers of symptoms were 5.9 (2.8) and 6 (0–14) respectively. Most frequently reported symptoms were decreased desire (77.8%), decreased arousal (71.4%), and vaginal dryness 68.4%). On a scale from 0 (no impact) to 10 (maximal impact), the most important impact was reported for sexual life (mean: 6.6±3.5) followed by psychological condition/self-image (mean 5.4±3.1), and relations with partners (mean: 5.1±3.4). Only 13.6% of participants had received information on GUSM prior to the survey.
Conclusions |
GUSM remains underdiagnosed and underestimated in BC survivors who receive HT, although it is among most frequent and disabling side effects of HT. Awareness should be increased among physicians, along with information to women. Early detection and treatment of symptoms and prophylaxis of GUSM in at-risk women should be implemented.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Hormonotherapy, Genitourinary syndrome of menopause
Plan
Vol 111 - N° 4
P. 347-355 - avril 2024 Retour au numéro
Article précédent
- Impact of the withdrawal of macrotextured implant on reconstruction practices
- Maxime Martinez, Clémentine Jankowski, Laura Vincent, Pierre Burnier, Charles Coutant
- Analyse des effets des inhibiteurs de l’aromatase en traitement prolongé chez les femmes ménopausées atteintes d’un cancer du sein non métastatique hormonodépendant ayant déjà reçu cinq ans d’hormonothérapie adjuvante : revue systématique et méta-analyse
- Kossi Clément Trenou, Miceline Mésidor, Caroline Diorio, Aida Eslami, Denis Talbot
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?